U.S. Pharmacovigilance showcase estimate was esteemed over USD 1 billion of every 2015, and anticipated to witness 10.7% CAGR from 2016 to 2024 to outperform USD 2.5 billion by 2024. The global pharmacovigilance (PV) & drug safety software market size was estimated at USD 124.6 million in 2016 and is expected to exhibit a CAGR of 6.5% over the forecast period. Increasing incidence of adverse drug reactions (ADR) are expected to propel the demand for pharmacovigilance (PV) software in the coming years. Increasing death rates attributable to antagonistic medication occasions and emerging patient concerns relating to wellbeing and viability of medications will drive industry development. Global Pharmacovigilance Market expected to Reach US$6.1 bn by 2020 expanding at a CAGR of 14.2% from 2015 to 2020 and also expected to reach a market size of $8.23 billion by 2022. By 2020, the size of the global pharmaceutical market is anticipated to grow to USD 1.3 trillion, with the E7 countries -- Brazil, China, India, Indonesia, Mexico, Russia and Turkey. The rapid induction in the market throws up the challenges of monitoring Adverse Drug Reactions (ADRs) over large population base.

19th Pharmacovigilance 2019 will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry.  The entire program will cover the detection, analysis and prevention of adverse drug reactions.  It will be studied with the help of case studies and industry experiences.  Hence, this conference will provide an important platform for pharmacovigilance stakeholders to discuss and share best practices in expediting Pv development. What does the future hold for pv? Find out at our conference on opportunities and activities shaping pv to 2020 with respect to regulations, technologies and services. Learn and know on what are drug producers and service providers doing? What regulations and technologies influence the current PV field? You can also discover at 19th Pharmacovigilance 2019 on spending forecasts for PV (US, the EU and Asia).

It gives me great pleasure in welcoming all of you to the Virtue Insight’s 19th Pharmacovigilance 2019.  I wish and pray that all our efforts will be beneficial to our industries and to our country at large.